Press Releases

Name: Medicure Inc.
Address: 1250 Waverley Street, Winnipeg, Manitoba, R3T 6C6
Price range: unknown

Medicure Provides Update on Tardoxal and TEND-TD Study August 13, 2014	Medicure Announces Shares for Debt Settlement July 11, 2014	Medicure Announces Grant of Options July 7, 2014
Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore July 3, 2014	Medicure Comments on Recent Trading Activity April 15, 2014	Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services April 14, 2014
Medicure Reports Financial Results for the Third Quarter Fiscal 2014 March 26, 2014	Medicure Reports Second Quarter Financial Results for Fiscal 2014 January 28, 2014	Medicure Reports First Quarter Financial Results for Fiscal 2014 October 30, 2013
Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT® October 11, 2013	Medicure Reports Financial Results for Fiscal 2013 September 27, 2013	Medicure Announces Grant of Options May 10, 2013
Medicure Reports Third Quarter Financial Results for Fiscal 2013 April 29, 2013	Dr. Albert D. Friesen to File Early Warning Report February 28, 2013	Medicure Reports Second Quarter Financial Results for Fiscal 2013 January 28, 2013
Medicure Appoints Brent Fawkes to Board of Directors January 22, 2013	Medicure Announces Filing of sNDA for AGGRASTAT Label Change January 8, 2013	Medicure Announces Agreement to Promote Aggrastat® in the Commonwealth of Puerto Rico November 5, 2012
Medicure Completes Share Consolidation November 1, 2012	Medicure Reports First Quarter Financial Results for Fiscal 2013 October 30, 2012	Medicure Announces Intention to Seek Expanded Aggrastat Label October 2, 2012
Medicure Announces Development of Novel AGGRASTAT Formulation September 26, 2012	Medicure Announces Proposed Fifteen to One Share Consolidation September 21, 2012	Medicure Reports Financial Results for Fiscal 2012 September 19, 2012
Medicure Announces Commencement of Enrollment in SAVI-PCI Trial of AGGRASTAT May 10, 2012	Medicure Reports Third Quarter 2012 Financial Results April 20, 2012	Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI January 30, 2012
Medicure Reports Second Quarter 2012 Financial Results January 25, 2012	Medicure Provides Update on TEND-TD Phase II Clinical Trial January 23, 2012	Medicure Reports First Quarter 2012 Financial Results November 29, 2011
Medicure Announces Graduation to TSX Venture Exchange October 21, 2011	Medicure Reports Financial Results for Fiscal 2011 September 28, 2011	Medicure Announces Appointment of New CFO September 22, 2011
Medicure Announces Appointment of Dawson Reimer as President and Chief Operating Officer July 25, 2011	Medicure Announces Birmingham Debt Settlement July 18, 2011	Medicure Announces Grant of Options July 18, 2011
Medicure Announces Executive Officer Change July 15, 2011	Medicure International and Iroko Cardio Sign an Agreement for the Advancement of AGGRASTAT® Worldwide July 6, 2011

Newer | Older

Press Releases

Medicure Provides Update on Tardoxal and TEND-TD Study

Medicure Announces Shares for Debt Settlement

Medicure Announces Grant of Options

Medicure Acquires Minority Position in Pharmaceutical Manufacturer, Apicore

Medicure Comments on Recent Trading Activity

Medicure Engages Knight Therapeutics Inc. to Provide Advisory Services

Medicure Reports Financial Results for the Third Quarter Fiscal 2014

Medicure Reports Second Quarter Financial Results for Fiscal 2014

Medicure Reports First Quarter Financial Results for Fiscal 2014

Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT®

Medicure Reports Financial Results for Fiscal 2013

Medicure Announces Grant of Options

Medicure Reports Third Quarter Financial Results for Fiscal 2013

Dr. Albert D. Friesen to File Early Warning Report

Medicure Reports Second Quarter Financial Results for Fiscal 2013

Medicure Appoints Brent Fawkes to Board of Directors

Medicure Announces Filing of sNDA for AGGRASTAT Label Change

Medicure Announces Agreement to Promote Aggrastat® in the Commonwealth of Puerto Rico

Medicure Completes Share Consolidation

Medicure Reports First Quarter Financial Results for Fiscal 2013

Medicure Announces Intention to Seek Expanded Aggrastat Label

Medicure Announces Development of Novel AGGRASTAT Formulation

Medicure Announces Proposed Fifteen to One Share Consolidation

Medicure Reports Financial Results for Fiscal 2012

Medicure Announces Commencement of Enrollment in SAVI-PCI Trial of AGGRASTAT

Medicure Reports Third Quarter 2012 Financial Results

Medicure Announces AGGRASTAT Clinical Trial: SAVI-PCI

Medicure Reports Second Quarter 2012 Financial Results

Medicure Provides Update on TEND-TD Phase II Clinical Trial

Medicure Reports First Quarter 2012 Financial Results

Medicure Announces Graduation to TSX Venture Exchange

Medicure Reports Financial Results for Fiscal 2011

Medicure Announces Appointment of New CFO

Medicure Announces Appointment of Dawson Reimer as President and Chief Operating Officer

Medicure Announces Birmingham Debt Settlement

Medicure Announces Grant of Options

Medicure Announces Executive Officer Change

Medicure International and Iroko Cardio Sign an Agreement for the Advancement of AGGRASTAT® Worldwide

Stay Connected

Sign up for our newsletter

About

Products

News and Media

Investors

Online Pharmacy

Contact Us